Presence of <i>IDH2</i> and <i>TP53</i> mutations significantly reduces survival of patients with chondrosarcoma

IDH2 and TP53 mutations are enriched in dedifferentiated CS and are significant, independent predictors of adverse survival, regardless of tumor grade. These findings support IDH2 mutation status as clinically meaningful prognostic biomarker that may allow risk stratification and clinical decision-making in CS patients.